Literature DB >> 6507489

Teratogenicity of anticonvulsant drugs. II: A prospective study.

T E Kelly, P Edwards, M Rein, J Q Miller, F E Dreifuss.   

Abstract

To 468 women with epilepsy enrolled in the study, 171 children were born and evaluated prospectively. The mothers in this group were characterized by low socioeconomic status, high frequency of tonic-clonic generalized seizures, and use of combinations of anticonvulsants. Approximately 30% of infants exposed to diphenylhydantoin in utero had minor craniofacial and digital changes. The infants did not show an increased rate of growth retardation, mental retardation, or major malformations. It is suggested that the nature of the association of birth defects and maternal epilepsy is complex and that the teratogenicity of anticonvulsant drugs plays only a minor role in this association. The sample size necessary to demonstrate a two- to threefold increase in malformations is beyond the capability of a single center.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6507489     DOI: 10.1002/ajmg.1320190303

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  10 in total

Review 1.  Drug-induced congenital defects: strategies to reduce the incidence.

Authors:  M De Santis; B Carducci; A F Cavaliere; L De Santis; G Straface; A Caruso
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Advances in Epidemiological Methods and Utilisation of Large Databases: A Methodological Review of Observational Studies on Central Nervous System Drug Use in Pregnancy and Central Nervous System Outcomes in Children.

Authors:  Zixuan Wang; Phoebe W H Ho; Michael T H Choy; Ian C K Wong; Ruth Brauer; Kenneth K C Man
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

3.  Valproic acid therapy and neural tube defects.

Authors:  A S Garden; R J Benzie; E M Hutton; D J Gare
Journal:  Can Med Assoc J       Date:  1985-04-15       Impact factor: 8.262

Review 4.  Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.

Authors:  Jennifer Weston; Rebecca Bromley; Cerian F Jackson; Naghme Adab; Jill Clayton-Smith; Janette Greenhalgh; Juliet Hounsome; Andrew J McKay; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2016-11-07

Review 5.  Risk-benefit assessment of anticonvulsants in women of child-bearing potential.

Authors:  P G Cleland
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

6.  Fetal phenytoin exposure, hypoplastic nails, and jitteriness.

Authors:  S W D'Souza; I G Robertson; D Donnai; G Mawer
Journal:  Arch Dis Child       Date:  1991-03       Impact factor: 3.791

7.  Can we ensure the safe use of known human teratogens? Introduction of generic isotretinoin in the US as an example.

Authors:  Margaret A Honein; Cynthia A Moore; J David Erickson
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

8.  Association of maternal chronic disease with risk of congenital heart disease in offspring.

Authors:  Hsin-Hsu Chou; Meng-Jiun Chiou; Fu-Wen Liang; Lea-Hua Chen; Tsung-Hsueh Lu; Chung-Yi Li
Journal:  CMAJ       Date:  2016-10-11       Impact factor: 8.262

Review 9.  Management of epilepsy during pregnancy.

Authors:  Dina Battino; Torbjörn Tomson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child.

Authors:  Rebecca Bromley; Jennifer Weston; Naghme Adab; Janette Greenhalgh; Anna Sanniti; Andrew J McKay; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2014-10-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.